Imaging of malignant melanoma and metastases with 1Z3iodine N-2 djethyl aminoethyl 4-iodobenzamide (123I-BZA

Imaging malignant melanoma with 18F-5-FPN

“…The first molecule used in a-c One mouse shows two individual small (1 -2 mm) lesions on the lung surface (c red arrows) with high uptake on the PET image (b red arrows) at 21 days after injection of B16F10 cells, but no uptake was seen at 14 days (a). d-f Another mouse shows diffuse lung uptake on the PET images at 14 days (d) and 21 days (e) after injection, which has a corresponding abnormality visible in the lung tissue (f) clinical trials was N-[2-diethylamino-ethyl]4-iodobenzamide) (iodoBZA) labelled with 123 I which has a sensitivity of 81 % and a specificity of 100 % for malignant melanoma imaging [27]. However, the mechanisms involved in the ability of radioiodine-labelled BZAs to image melanoma were misunderstood at first.…”

Melanoma-targeted delivery system (part 1): Design, synthesis and evaluation of releasable disulfide drug by glutathione

“…Among all the different molecular targets investigated, melanins are relevant, as they are detected in more than 90% of primary melanoma cases and in 30e50% of metastatic lesions [16]. The capacity of these amorphous, irregular polymers to bind to many drugs, especially those with coplanar fused aromatic rings and/or polyamine side chains, make it a promising target for a pigmented melanoma-targeting strategy [11,17]. Based on these findings, in the last two decades our research group has developed arylcarboxamide families that have potential applications for PET imaging [18e20] and/or targeting radionuclide therapy [21,22] of melanoma due to their rapid, specific and long-lasting tumour uptake.…”

A review of the Scientific highlights at the European Association of Nuclear Medicine Congress, Vienna 1991

“…Iodobenzamide derivatives for melanoma diagnosis and therapy Moreau et al (1991) and Michelot et al (1991) reported on derivatives of iodobenzamide (BZA) as melanomaspecific radiopharmaceuticals for diagnosis and therapy. From a previous experimental study its diagnostic utility had become apparent.…”

“…The normalized lSFD G uptake in metastases (lymph nodes, liver, adrenals) ranged between 2.1 and 13.1 prior to 1.00 1.50 2.00 2.50 3.00 3.50 4,00 4.50 5.00 5. therapy and decreased distinctly after chemotherapy (fotemustin, 200 rag, 30 rain infusion) beginning within hours and lasting for 1 week. Michelot et al (1991) reported the results of the clinical trial evaluating N-(2-diethylaminoethyl) 4-iodobenzamide or BZA as an imaging agent of MM (Brevet n°8901898, 02/14/1989, France). A total of 78 investigations in 70 stationary patients (age 33-89 years) was reported as follows: group I, cutaneous and ocular, primary melanoma (n=14 studies); group II, metastasis and documented recurrence of M M (n = 27); group III, complete clinical remission, follow-up of patients after treatment (n = 32); group IV, non-melanoma pathology (n--5).…”